Gland Pharma is a Hyderabad-based injectables-focused pharmaceutical company whose quarter comes against a backdrop of accelerating US generics momentum, a shortage-driven demand tailwind in sterile injectables, and a Cenexi turnaround in Europe that is still early in its margin climb. The print will speak most directly to whether consolidated EBITDA margin can close the gap to management's 30% near-term guide from Q1 FY27's 27%, and how Cenexi progresses from a 4% EBITDA margin toward the double-digit level guided by year-end.
| Results date | November 06, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 18,003 Mn |
| Previous quarter PAT | Rs. 3,170 Mn |
| Previous quarter EBITDA margin | 27% |
| Market cap | Rs. 52,104.66 Cr |
| CMP | Rs. 3,159.0 |
The Board of Directors will meet on November 6, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026.
The earnings call is scheduled the same day, November 6, 2026, at 18:30 IST.
The quarter tests whether Gland Pharma can convert a strong US run-rate into margin: Q1 FY27 US revenue of Rs. 9,810 Mn grew 32% YoY, and the September quarter added three ANDA approvals (Sugammadex Sodium on July 28, Atropine Sulfate on July 31, Levocarnitine on September 30, 2026) plus the Sugammadex Day-1 launch.
The demand backdrop is a tailwind management has explicitly flagged as guidance upside — active US drug shortages rose to 227 in Q2 2026, with sterile injectables at 71% of them, and Gland is among the manufacturers of shortage-listed carboplatin — though generic price deflation continues.
On costs, the company itself flagged a raw-material headwind expected in Q2-Q3 as the inventory buffer depletes, while the Section 232 generic tariff exemption held through the quarter and USD/INR exited September near the August average of 95.47, so the ~5-point forex contribution Q1 enjoyed flattens rather than builds. Cenexi is the margin swing: Q1 ran at EUR48 million revenue with EUR2 million EBITDA (4%), and management guided to a better Q2 YoY as France-heatwave-delayed quality releases flow through, en route to double-digit EBITDA percentage by year-end.
The call, the last before incoming group CEO Deepak Sapra takes charge on November 16, 2026, will also be probed on the maintained 12-13% constant-currency FY27 revenue growth guidance (excluding GLP-1).
Performance vs guidance tracking: Guidance scorecard from the Q1 FY27 and Q4 FY26 calls to interrogate on this call:
Leadership transition and Novelstar completion
Dundigal CAPA and promoter overhang: Regulatory and ownership follow-ups flagged for the call:
Metric watch: US momentum, R&D and ANDA cadence
Management expects limited GLP-1 revenue over the next 3 years, with major US volumes around FY30-31 as patents expire; interim revenue will come primarily from tech-transfer fees. Exhibit batches and filings are expected in Q3 or the latter half of FY27, and GLP-1 is excluded from FY27 guidance.
Yes — Cenexi turned EBITDA positive in Q3 FY26 with EUR50 million revenue and EUR1 million EBITDA, and posted EUR48 million revenue with EUR2 million EBITDA in Q1 FY27. Management has guided to a double-digit EBITDA percentage by year-end and high single-digit margins on near-EUR200 million revenue for FY27.
An unannounced cGMP inspection of the Dundigal Formulation Facility from October 12-23, 2026 concluded with 4 Form 483 observations, which management describes as procedural in nature, not repeated and not data-integrity related. A CAPA is to be submitted within the stipulated period; the Vizag inspection in August-September 2026 had ended with zero Form 483 observations.
Management has guided to 12%-13% consolidated revenue growth for FY27 in constant currency, excluding GLP-1 upside. Q1 FY27 reported revenue grew 20% YoY to Rs. 18,003 Mn, above the guide, with the US line up 32% YoY.
Disclaimer: This earnings preview is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.